New drugs for rheumatoid arthritis

N Engl J Med. 2004 May 20;350(21):2167-79. doi: 10.1056/NEJMra032906.
No abstract available

Publication types

  • Research Support, U.S. Gov't, P.H.S.
  • Review

MeSH terms

  • Adalimumab
  • Antibodies, Monoclonal / adverse effects
  • Antibodies, Monoclonal / therapeutic use
  • Antibodies, Monoclonal, Humanized
  • Antirheumatic Agents / adverse effects
  • Antirheumatic Agents / therapeutic use*
  • Arthritis, Rheumatoid / drug therapy*
  • Arthritis, Rheumatoid / immunology
  • Etanercept
  • Female
  • Humans
  • Immunoglobulin G / adverse effects
  • Immunoglobulin G / therapeutic use
  • Infliximab
  • Interleukin 1 Receptor Antagonist Protein
  • Isoxazoles / adverse effects
  • Isoxazoles / therapeutic use
  • Leflunomide
  • Pregnancy
  • Receptors, Tumor Necrosis Factor / therapeutic use
  • Sialoglycoproteins / adverse effects
  • Sialoglycoproteins / therapeutic use
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antirheumatic Agents
  • IL1RN protein, human
  • Immunoglobulin G
  • Interleukin 1 Receptor Antagonist Protein
  • Isoxazoles
  • Receptors, Tumor Necrosis Factor
  • Sialoglycoproteins
  • Tumor Necrosis Factor-alpha
  • Infliximab
  • Adalimumab
  • Leflunomide
  • Etanercept